• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Taiwanese Firm Courts Brazil for Biosimilar Partnership

Article

September 21, 2015.

Emerging Taiwanese biosimilars company JHL Biotech has hosted a delegation of Brazilian government officials and biotech executives in support of a partnership bid to produce affordable, world-class biosimilars. The delegation included Dr. Antonio Werneck, President of In Vitro Brazil, Dr. Augusto Raupp, President of the Research Foundation of the State of Rio de Janeiro (FAPERJ), and Mr. Tande Vieira of the Executive Group of Life Sciences of the Industrial Complex of Rio de Janeiro.

Brazil has become an increasingly attractive target for biosimilar developers, reports JHL Biotech, because of the Brazilian government's strong encouragement to its domestic manufacturers to work with international partners.

The delegation toured JHL's research and manufacturing facilities and observed its GMP production activities.

Related Videos